IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.

OBJECTIVE IDH-mutant grade 4 astrocytomas (AIDHmut/G4) are divided into primary de novo (pAIDHmut/G4) and secondary with a history of prior lower-grade gliomas (LGGs; sAIDHmut/G4). The mutational spectrum and DNA methylation patterns are homogeneous within de novo pAIDHmut/G4 and evolved sAIDHmut/G4, but the two groups have different diagnoses, management, and outcomes. This study sought to systematically compare the clinical, pathological, and survival characteristics between them. METHODS Of the 871 grade 4 astrocytomas with data for IDH mutation, 698 (80.1%) were primary and 173 (19.9%) were secondary. Of the 698 primary tumors, 103 (14.8%) were pAIDHmut/G4, and of the 173 secondary tumors, 108 (62.4%) were sAIDHmut/G4. Clinical, pathological, and survival features were compared between pAIDHmut/G4 and sAIDHmut/G4. Multivariate analyses were performed to identify prognostic factors. RESULTS Patients with sAIDHmut/G4 had significantly shorter median overall survival (OS; 11.8 vs 34.2 months, hazard ratio [HR] 2.69, 95% confidence interval [CI] 1.367-5.306, p = 0.004) and progression-free survival (PFS; 8.5 vs 24.3 months, HR 2.83, 95% CI 1.532-5.235, p = 0.001) than patients with pAIDHmut/G4. In patients with sAIDHmut/G4, resection status and chemotherapy were independent prognostic factors for OS and PFS; in patients with pAIDHmut/G4, LGG component, resection status, and O6-methylguanine DNA methyltransferase promoter methylation were independent prognostic factors. The therapeutic strategies of LGGs did not influence survival of patients with sAIDHmut/G4, but patients who had not received radiotherapy or chemotherapy when they were diagnosed with LGGs were found to benefit from radiotherapy or chemotherapy when they progressed to sAIDHmut/G4. CONCLUSIONS The different clinical characteristics, survival, and risk factors between sAIDHmut/G4 and pAIDHmut/G4 provide a reference to guide treatment decisions in AIDHmut/G4.

[1]  Jing Zhang,et al.  Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas , 2022, Cancer biology & medicine.

[2]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[3]  Wei-wei Wang,et al.  Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas , 2021, Modern Pathology.

[4]  David T. W. Jones,et al.  Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis , 2020, Acta Neuropathologica.

[5]  Shuai Liu,et al.  Clinical practice guidelines for the management of adult diffuse gliomas. , 2020, Cancer letters.

[6]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[7]  C. Ida,et al.  Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of “dual-genotype” IDH-mutant infiltrating gliomas , 2020, Acta Neuropathologica.

[8]  B. Policeni,et al.  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques , 2019, American Journal of Neuroradiology.

[9]  Jennifer S. Yu,et al.  Malignant Transformation of Molecularly Classified Adult Low Grade Glioma. , 2019, International journal of radiation oncology, biology, physics.

[10]  Atique U. Ahmed,et al.  Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation. , 2019, JCO clinical cancer informatics.

[11]  M. Kool,et al.  Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.

[12]  Tao Jiang,et al.  Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor , 2018, Cell.

[13]  K. Aldape,et al.  Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial , 2018, JAMA oncology.

[14]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[15]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[16]  Jennifer S. Yu,et al.  Risk Factors for Malignant Transformation of Low-Grade Glioma. , 2017, International journal of radiation oncology, biology, physics.

[17]  Satoshi O. Suzuki,et al.  Insular primary glioblastomas with IDH mutations: Clinical and biological specificities , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.

[18]  Luca Magnani,et al.  Poised epigenetic states and acquired drug resistance in cancer , 2014, Nature Reviews Cancer.

[19]  M. Franchini,et al.  Beyond immunohaematology: the role of the ABO blood group in human diseases. , 2013, Blood transfusion = Trasfusione del sangue.

[20]  T. Jiang,et al.  Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. , 2012, Neuro-oncology.

[21]  Y. Hayashi,et al.  The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma. , 2011, Japanese journal of clinical oncology.

[22]  C. Sommer,et al.  MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma , 2010, International journal of cancer.

[23]  A. Brandes,et al.  O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. , 2010, Neuro-oncology.

[24]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[25]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[26]  M. Nistér,et al.  Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas , 2007, Acta Neuropathologica.

[27]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[28]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Na He,et al.  ABO blood groups and risk of cancer: a systematic review and meta-analysis. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[30]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.